Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Conditions
Keywords
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Brief summary
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
Detailed description
The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®. 1. Unknown adverse events (in particular, serious adverse events) 2. Identification of adverse events occurred in the real practice. 3. Factors that are considered to affect on safety. 4. Factors that are considered to affect on effectiveness
Interventions
DRUGSorafenib (Nexavar, BAY43-9006)
Daily dose, dosage frequency and duration will be decided by physicians.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 91 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events collection | From start of treatment to 4 weeks after discontinuation of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Duration of treatment, dosage and indication | Whole treatment period |
| Tumor status | Whole treatment period |
| Performance status | Whole treatment period |
Countries
South Korea
Outcome results
None listed